Exome Sequencing Reveals Immune Genes as Susceptibility Modifiers in Individuals with α₁-Antitrypsin Deficiency

Chiara Rigobello¹, Simonetta Baraldo¹, Mariaenrica Tinè¹, Ilaria Ferrarotti², Angelo Guido Corsico²,³, Erica Bazzan¹, Graziella Turato¹, Elisabetta Balestro¹, Davide Biondini², Giorgio Valle¹, Marina Saetta¹ & Manuel G. Cosio¹,⁵

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder associated to early onset emphysema, mainly imputable to Pi*ZZ genotype. In spite of the serious potential effects, many AATD individuals do not develop emphysema. To identify genes/variants potentially involved in emphysema development we studied 4 AATD families. Each family had at least one affected sibling with emphysema and one non-affected. Whole Exome Sequencing (WES) was performed on genomic DNA isolated from 9 individuals with AATD (4 affected/5 non-affected). Genetic variants confirmed at least in three families were prioritized using QueryOR and network analysis was used to verify enriched pathways. In affected subjects: 14 genes (57% immune-related) segregated in a recessive model and 21 (29% immune-related) in a dominant model. In non-affected subjects: 21 genes (43% immune-related) segregated in a recessive model and 50 (24% immune-related) in a dominant model. In affected siblings immune genes had an activating function, while immune-suppressing in non-affected siblings involving antigen processing, MHC-I presentation, TCR and PD-1 signalling. This study describes possible genetic susceptibility factors for emphysema development in AATD, and suggests that gene variants involved in regulation of immune homeostasis and maintenance of self-tolerance contribute to the development or suppression of the disease.

SERPINA1 gene codifies for α₁-antitrypsin (AAT), a protease inhibitor, archetype member of the superfamily of Serine Protease Inhibitors (SERPINs) characterized by their ability to inhibit proteases that possess the amino acid serine in their active site. AAT is part of a serpins cluster on chromosome 14q32.1 that includes: corticosteroid binding globulin (SERPINA6), α₁-antitrypsin-like pseudogene, α₁-antitrypsin (SERPINA1), protein C inhibitor, α₁-chymotrypsin. This group of genes is in conserved linkage with the immunoglobulin heavy chain gene¹. AAT is the main inhibitor of proteases in the lung, providing more than 90% of the defence against the elastolytic activity of neutrophil elastase². As an acute phase reactant, its tissue concentrations can increase by as much as 11 folds during an inflammatory response and, as recently become evident, AAT has important regulatory and anti-inflammatory properties, affecting both the innate and adaptive immune systems³–⁵.

The wild type form of SERPINA1, corresponding to the "M" allele (Pi*M), produces normal levels of serum protein. Most of the severe α₁-antitrypsin deficiency (AATD) cases are associated with Pi*ZZ genotype, a result of a missense mutation (p.E366K-c.1096G>A rs28929474) causing an aminoacidic substitution from a negatively charged Glutamate (GAG) to a positively charged Lysine (AAG). This mutation induces a conformational change favouring abnormal protein folding and polymerization, resulting in AAT retention within the endoplasmic reticulum of the liver and, consequently, very low serum AAT levels. Some very rare variants of the
SERPINA1 are secondary to insertion/deletion, frame-shift, stop codon mutations, with a consequent lack of production of the AAT protein and no detectable plasma levels (PiNull)⁶,⁷.

AATD is one of the most common respiratory hereditary disorders affecting Caucasians of European descent⁸. The genetic abnormality is inherited in an autosomal co-dominant pattern and is characterized by a high risk for development of severe emphysema, often at early age, and a lesser risk for the development of liver disease and, rarely, panniculitis⁹,¹⁰. The pathogenesis of emphysema in this condition is complicated and involves not only the loss of the antielastase properties of AAT, but also a severe adaptive immune inflammation in the lung, as it has been recently shown¹¹. The inflammatory immune reaction is not surprising in view of the potent anti-inflammatory properties of AAT, which are lost with its deficiency³,⁴,⁵.

In spite of its serious potential effects, the development of emphysema in the setting of severe AAT deficiency is highly variable and there is a large discrepancy between the predicted numbers of Pi*ZZ subjects in the population and the actual number of individuals that are recognized to have lung disease¹¹–¹³. Furthermore, even when cigarette smoking (an important risk factor for the development of emphysema in Pi*ZZ individuals) is considered, there is a substantial variability on the severity of pulmonary disease: lung function can be well preserved in some Pi*ZZ smokers, but severely impaired in some non-smokers¹⁴. Such evidences strongly suggest that the phenotypic expression of the disease could be influenced by an incomplete penetrance and/or variable expressivity of the Pi* Z allele. This finding is not surprising since it has become evident that traits inherited in a simple Mendelian fashion are rare in nature, due to the interaction with susceptibility genetic modifiers and environmental factors, which could affect phenotypes in subtle or profound ways¹⁵,¹⁶. Likely, the presence of genetic susceptibility modifiers could explain the variable phenotype seen in AATD.

In this study we used Whole Exome Sequencing (WES) technology¹⁷ to identify variants that might potentially account for the variability in penetrance and expressivity of the disease induced by the AATD genetic disorder. Towards this aim, we analysed whole exome in AATD siblings within the same family with extreme phenotypes and the actual number of individuals that are recognized to have lung disease¹¹–¹³. Furthermore, even when cigarette smoking (an important risk factor for the development of emphysema in Pi*ZZ individuals) is considered, there is a substantial variability on the severity of pulmonary disease: lung function can be well preserved in some Pi*ZZ smokers, but severely impaired in some non-smokers¹⁴. Such evidences strongly suggest that the phenotypic expression of the disease could be influenced by an incomplete penetrance and/or variable expressivity of the Pi* Z allele. This finding is not surprising since it has become evident that traits inherited in a simple Mendelian fashion are rare in nature, due to the interaction with susceptibility genetic modifiers and environmental factors, which could affect phenotypes in subtle or profound ways¹⁵,¹⁶. Likely, the presence of genetic susceptibility modifiers could explain the variable phenotype seen in AATD.

In this study we used Whole Exome Sequencing (WES) technology¹⁷ to identify variants that might potentially account for the variability in penetrance and expressivity of the disease induced by the AATD genetic disorder. Towards this aim, we analysed whole exome in AATD siblings within the same family with extreme phenotypes of the disease (one sibling affected and one non-affected), and compared the variants across unrelated families. Restricting the analyses to AATD siblings with opposite phenotypes could limit heterogeneity and help the identification of factors contributing to the development of emphysema¹⁸. Some of the results of this study have been reported in the form of an abstract¹⁹.

**Results**

**Study population.** We studied 4 families from the AATD Italian Registry with siblings concordant for genotype, but with discordant phenotypes (emphysema/no emphysema). Clinical characteristics are reported in Table 1. All siblings had severe AATD, defined by the carriage of the Pi*ZZ (families 3, 185, 237) or Pi*Z/0_brescia genotypes (family 114). Whole Exome Sequencing confirmed the genotype in all individuals. Each family studied had at least one affected sibling with emphysema and a non-affected sibling, free of disease. The population studied comprised 9 subjects, 4 affected and 5 non-affected, with a predominance of females (n = 6; 66.7%) and a mean age of 56.5 ± 15.5 years old. One of the affected subjects had normal FEV₁ but had significant dyspnea, emphysema and bronchiectasia by CT scan and reduced diffusion capacity (Table 1). Two of the affected subjects were ex-smokers with a smoking history of less than 20 pack-years and who had quit smoking for more than 10 years; the rest were never smokers.

**WES analysis.** Whole Exome Sequencing generated an average of 3.6 × 10⁷ reads mapped to the reference genome at a mean depth of 105.4-fold coverage per sample. The 93.5% of exome was covered at minimum with a mean depth of 105.4-fold coverage per sample. The 93.5% of exome was covered at minimum with average coverage, uniformity, transition/transversion ratio) exceeded the normal standards applied for the identification of germline variants, making our results robust (a complete description of WES statistic, coverage and type of variants is shown on Supplementary Tables S1, S2 and Supplementary Fig. S1). After quality control adjustment, a total of 77204 variants remained for analysis. Table 2 summarizes the type of variants found in our population. For all subsequent analysis, we excluded variants located on not confirmed transcripts (20730) or on Untranslated

Table 1. Subjects characteristics. Bold characters identify affected siblings. *This patient underwent lung transplantation. †In spite of preserved FEV₁, this patient suffered from dyspnea and productive cough. The diffusing capacity of the lungs for carbon monoxide (DL_{CO}) was reduced and thoracic HRCT showed emphysema and bronchiectasis.

| Family ID | Subjects ID | Sex | Age (yrs) | AAT level (mg/dL) | Genotype | FEV₁ (% pred) | Smoking History |
|-----------|-------------|-----|-----------|-----------------|----------|---------------|----------------|
| 3         | AWI         | F   | 67        | 18              | ZZ       | 94            | Non Smoker     |
| 3         | AWI         | M   | 65        | 43              | ZZ       | 106           | Non Smoker     |
| 237       | AWK*        | M   | 60        | 22              | ZZ       | 25            | Ex Smoker      |
| 185       | AWL         | F   | 73        | 37              | ZZ       | 57            | Non Smoker     |
| 185       | AWL         | M   | 71        | 36              | ZZ       | 85            | Non smoker     |
| 114       | BIR         | F   | 53        | 28              | ZZ       | 102           | Non Smoker     |
| 114       | BQO         | F   | 43        | 35              | ZZ       | 100           | Non Smoker     |
| 114       | BIP         | M   | 50        | 23.3            | ZQ0      | 32            | Ex Smoker      |
| 114       | BIP         | F   | 47        | 20              | ZQ0      | 99            | Non Smoker     |
Regions (5′UTR and 3′UTR) (14597). Using ANNOVAR and dbNSFP database (v.2.9), 41877 functionally annotated variants were identified: 49.5% (20748) synonymous and 50.5% (21129) non-synonymous. Among the non-synonymous 19751 were missense, 240 nonsense, 612 frameshift, 447 inframe, 59 stop-loss and 20 stop-gain. Of the 77204, 7.6% (5914) variants were classified as rare variants (GMAF ≤ 1%), 4.3% (3345) were novel and 1.4% (1058) were insertions-deletions.

**Variant filtering and annotation.** A flow chart of the filtering approach applied to the 77204 variants found is shown in Fig. 1. Among the 41877 functionally annotated variants (synonymous and non-synonymous), we considered only high confidence variants with alternative allele coverage > 30 (34725). After synonymous exclusion, non-synonymous variants were 17373. In addition, after excluding variants with minor allele in reference (false positive)20, the number of variants was 16319.

As the number of potential segregating variants is large, particularly in small family units (sibling pairs), we have limited the number of candidate genes restricting variants analysis to those confirmed at least in three families and we have taken into consideration two patterns of inheritance: recessive and dominant models. Table 3 shows variants identified in affected subjects: 14 genes with 15 variants in the recessive model (57% immune-related) and 21 genes with 23 variants in the dominant model (29% immune-related). Figure 2A shows genes with recognized immune function identified in the affected subjects, none of which were present in the non-affected subjects. All these genes have been described to exert a pro-inflammatory function, affecting key steps involved in the immune response, such as: coagulation, complement and innate immunity (KNG1, THSD7B, IFIH1/MDA5), DC activation/maturation (IFIH1/MDA5, KNG1), ubiquitination antigen processing and presentation (MIB2, KLHL3), T cell function (AKNA, MS4A14, THSD7B, DNTTIP2) and B cell function (AKNA, DNTTIP2, MS4A14, PIK3AP1).

Table 4 shows variants identified in non-affected subjects: 21 genes with 21 variants in the recessive model (43% were immune-related genes), and 50 genes with 62 variants in the dominant model (24% were immune-related genes). Figure 2B shows genes with a recognized immune function identified in the non-affected subjects, none of which was present in the affected subjects. Contrary to what was found in the affected subjects, a significant number of the gene expressed in the non-affected group have been described to exert a suppressor function at the different steps of the immune cascade: complement and innate immune response (CPB2, PRDM1, TMEM173), antigen presentation (HLA alleles, mainly DRB1 DQB1), T and B cell functions (CD5, CD200, NFATC4).

None of the 5914 rare variants (GMAF ≤ 1%) were confirmed in three families, using our filtering criteria. Three novel variants were identified: TPTE 21:g.10951387T > G, missense, (in non-affected subjects, recessive inheritance model); ACBD3 1:g.226352490CTTTTTTT > CTTTTTTT, frameshift and LRCH4 7:g.100175472GTC > GC, frameshift (in affected subjects, dominant inheritance model). The alignment of these variants against the eutherian mammals in the Ensembl database show that they were all located in not-conserved regions suggesting that these substitutions were of little significance.

The implication of amino acids changes on protein function in affected and non-affected subjects under the two inheritance models according to CADD, DANN and PROVEAN scores rating are shown in the Supplementary Tables S3–S6.

**Pathways analysis.** Using Reactome and KEGG we investigated the possible functional significance, network interactions and biological pathways of the whole number of genetic variants, differentially found in affected
or non-affected individuals. Pathways mainly related to the immune system were significantly represented both in affected and non-affected subjects using Reactome (Supplementary Tables S7–S10) and confirmed in KEGG (data not shown). The pathways enriched in non-affected subjects such as cytokine signaling in immune system, interferon signaling, class I MHC mediated antigen processing and presentation were significant, even after False Discovery Rate (FDR) correction (Supplementary Tables S8, S10). Finally, enriched pathways were integrated using Enrichment map app in Cytoscape3, which translates data to a network where highly similar terms in both databases cluster together. This network analysis is shown in Fig. 3. Panel A shows the network analysis in affected subjects: enriched pathways include those related to the immune system (antigen processing and class I MHC antigen presentation). Other minor networks included diseases of signal transduction and lyase activity, possibly linked to DNA repair in response to oxidative stress. Panel B shows the network analysis for non-affected subjects: pathways of immune system (Interferon Gamma, TCR and PD-1 signalling) are predominantly enriched.

Discussion
The genetically induced α-1 antitrypsin deficiency (AATD) predisposes to the development of emphysema in which a severe adaptive inflammatory reaction, similar to the one seen in COPD with normal AAT levels, plays an important role. However, as seen in other genetically induced abnormalities, individuals with AATD often fail to express most, if not all, features of disease (emphysema, COPD), possibly due to the action of modifier genes. It is thus likely that the variable penetrance and expressivity of the Pi*ZZ genotype may reflect the action of unlinked modifier variants, a possibility that has never been investigated.

In this work, we used Whole Exome Sequencing (WES) to identify potential modifier genes/variants that might contribute to the development of emphysema in AATD. Our study of siblings of opposed phenotypes in four unrelated families, has provided description of sets of variants shared exclusively by affected subjects or exclusively by non-affected subjects with AATD. These results highlight the likely involvement of immunity in the development or suppression of the disease in subjects with AATD.

To our knowledge, this is the first description of possible genetic susceptibility factors influencing the risk of developing or avoiding the lung disease in AATD and possibly, by extension, in COPD with normal AAT levels. At difference with previous reports using WES in COPD, we did not filter for the exclusion of common variants since it is known that the phenotypic effects of some rare alleles are modified by common alleles. The variants segregating in affected and non-affected subjects differed substantially between the two groups, suggesting that different genetic factors might be modulating the penetrance of the AATD gene and thus the phenotype.

In the affected siblings, 14 genes with 15 variants in the recessive model (homozygosity), and 21 genes with 23 variants in the dominant model (heterozygosity) were identified in at least three out of four different pedigrees. Fifty-seven percent of the variants in the recessive model and 29% in the dominant model have recognized
important roles in innate and adaptive immunity, affecting activation of complement cascade, antigen presenta-
tion and regulation of immune responses as shown in Fig. 2. Of particular interest among the genes found, is the
presence in the affected pedigrees of the rs3747517 variant on IFIH1 gene that has been strongly associated with
susceptibility to autoimmune diseases23,24. This gene codes for an innate immune protein, which induces
the type I interferons and pro-inflammatory cytokine cascades. Similarly pertinent, because of their involvement in
autoimmunity, are AKNA and MIB2 genes. AKNA codifies for a transcription factor that specifically activates the
expression of CD40 receptor/ligand and is critical for antigen presentation, B and T cell development25. The MIB2
gene is an ubiquitin-protein ligase involved in the class I MHC mediated antigen processing and presentation26.

Table 3. Variants identified in affected subjects. Definition of abbreviations: SNP: single nucleotide
polymorphism; EVS = present in Exome Variant Server. *novel = not present in any public database. Genes
linked to immunity are shown in bold and underlined characters. 57% of the genes in the recessive inherited
model and 29% in the dominant were immune.
DNTTIP2 (a regulator of chromatin remodelling involved in B cells differentiation and maturation), IQCG (a calcium and calmodulin-dependent protein kinase) and PRDM16 (a repressor of TGF-beta signalling) have been shown to have enriched gene expression in patients with COPD and/or emphysema. The reproduction of these associations across different cohorts and different race/ethnic groups highlights the importance of variations in these genes in the mechanisms of COPD with and without AATD.

In the non-affected siblings, 21 genes with 21 variants in the recessive model, and 50 genes with 62 variants in the dominant model were identified and shared in at least three of the four families. At difference with the affected subjects, a high proportion of these variants had a known immune suppressor function. Forty-three percent of the variants in the recessive model and 24% in the dominant model have recognized important roles in innate and adaptive immunity. Among these, variants in HLA-C, HLA-DQB1 and HLA-DRB1 genes were found, a very significant finding in view of the important contribution of the HLA complex to immune disease susceptibility and pathogenesis. On this line, the MHC class II molecules HLA-DQB1 and HLA-DRB1, along with the MHC class I HLA-C, have been recently associated with resistance to systemic autoimmune diseases, such as systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis.

Possibly related to the lack of AATD induced abnormalities in non-affected subjects, is the considerable number of genes with a clear immune suppressive/regulatory function. CD5, a lymphocyte surface receptor, constitutively expressed by all T cells and a subset of mature B cells, is particularly important in the context of our study, since the variant we identified rs2229177 has been associated with better clinical outcomes in autoimmune diseases. CD5, acting as an immune inhibitor checkpoint equally to PD-1 and CTLA-4, is key in the maintenance of immune homeostasis.

The TMEM173 allele R232H, corresponding to our homozygous variant rs1131769, is a major regulator of the innate immunity and interferon response. Furthermore, CD200 (a membrane glycoprotein belonging to the immunoglobulin superfamily), PRDM1 and CPB2 were the other genes with important immune suppressive functions found in the non-affected siblings, but not in affected ones. Cytoscape network analysis confirmed that variants identified in our population have biological functions and important network interactions, which fit with the described immune mechanism in the production of emphysema. Overall, our results point towards a large contribution of regulatory molecules involved in the normal homeostasis of immune responses and the maintenance of self-tolerance. These factors act synergistically to orchestrate an immunological environment which could be conducive and promote the development of emphysema or, what is more relevant, to confer a resistance status, evading the disease. These findings support the concept that activation, or failure of suppression, of the innate and adaptive immune response, may well be responsible for the development of COPD and emphysema, both in AATD and COPD with normal AAT levels.

Our study has several limitations: the number of families studied is small, but it is an accepted norm in studies of Mendelian traits, especially when comparing opposed phenotypes in family settings. Indeed, WES is a powerful method to investigate genetic variation even within a small number of individuals. In particular, in human diseases characterized by considerable heterogeneity, these new technologies overcome the analysis of a single polymorphism, allowing to consider the effect of a set of variants in their entirety. Despite the small size of our study, we were able to replicate some of the findings of previous GWAS studies on lung function and co-expression network analyses in COPD, expanding the evidence linking immune system and lung abnormalities. The lack of quantitation of the extent of emphysema by computer-assisted analysis is a possible limitation in our study. However, all CTs were assessed independently by two thoracic radiologists and supported by measurements of diffusion capacity that can enhance the detection of emphysema. Another limitation to be considered would be the potential bias of smoking. There were two individuals with a smoking history in the study and, although marginal (ex-smokers of less than 20 pack-years who had stopped smoking from more than 15 years ago), this could have influenced the results.

**Figure 2.** The discriminating genes with immune functions and their targets. Panel A shows variants with recognized immune function in the affected subjects. All these genes have been described to exert a pro-inflammatory function (pro-inflammatory genes in black font). Panel B shows variants with recognized immune function identified in the non-affected subjects. Most of these genes exert an immune suppressor function (suppressor genes in green font, pro-inflammatory genes in black font).
| Gene name | SNP ID     | wild type allele | AWK (family 3) | AWL (family 185) | BIR (family 237) | BIP (family 114) |
|-----------|------------|------------------|----------------|------------------|------------------|------------------|
| **Recessive Inheritance Model** |            |                  |                |                  |                  |                  |
| AAK1      | rs66931661 | CTGT             | C/C            | C/C              | G/C              | G/C              |
| ABCB11    | rs2287622  | A                | G/G            | G/G              | G/G              |                  |
| ALG1L     | rs3828357  | T                | C/C            | C/C              | C/C              | C/C              |
| C1orf227  | rs10864004 | A                | G/G            | G/G              | G/G              | G/G              |
| CDS1      | rs2229177  | C                | T/T            | T/T              |                  |                  |
| CPB1      | rs1926447  | A                | G/G            | G/G              | G/G              |                  |
| CSNK1A1L  | rs9576175  | G                | T/T            | T/T              |                  |                  |
| HLA-C     | rs79636386 | A                | C/C            | C/C              | C/C              |                  |
| HLA-DQB1  | rs1049130  | A                | G/G            | G/G              | G/G              |                  |
| KRTAP19-4 | rs2298437  | T                | C/C            | C/C              |                  |                  |
| LCE5A     | rs2105117  | G                | A/A            | A/A              |                  |                  |
| MMRN2     | rs3750823  | C                | T/T            | T/T              |                  |                  |
| NFATC4    | rs7149586  | T                | C/C            |                  |                  | C/C              |
| PM20D1    | rs1361754  | A                | G/G            | G/G              |                  |                  |
| RTP1      | rs6764714  | C                | G/G            | G/G              |                  |                  |
| SIM2      | rs2073601  | C                | A/A            | A/A              |                  |                  |
| TINAG     | rs1058768  | T                | C/C            | C/C              |                  |                  |
| TMED5     | rs1060622  | G                | A/A            | A/A              |                  |                  |
| TMEF12    | rs1131769  | T                | C/C            |                  |                  | C/C              |
| TPTE      | novel*     | G                | T/T            | T/T              |                  |                  |
| ZC3H13    | rs9534264  | T                | A/A            |                  |                  |                  |
| **Dominant Inheritance Model** |            |                  |                |                  |                  |                  |
| ACBD3     | rs2386120  | T                | T/G            | T/G              |                  | T/G              |
| ALPK2     | rs9944810  | C                | G/A            | C/A              |                  |                  |
| ANKK1     | rs1890497  | G                | G/A            |                  |                  |                  |
| ART4      | rs11276    | C                | C/T            |                  |                  |                  |
| BBS12     | rs309370   | G                | G/A            |                  |                  |                  |
| BBS12     | rs13135778 | G                | G/A            |                  |                  |                  |
| C12orf50  | rs6923175  | CTA              | CTA/C          |                  |                  |                  |
| C12orf50  | rs7307438  | T                | T/A            |                  |                  |                  |
| CCDC144NL | rs79930314 | G                | G/T            |                  |                  |                  |
| CCDC144NL | rs79843086 | G                | G/T            |                  |                  |                  |
| CCHCR1    | rs130088   | G                | G/A            |                  |                  |                  |
| CD200     | rs2272022  | C                | G/A            |                  |                  |                  |
| CWF19L2   | rs659040   | G                | G/A            |                  |                  |                  |
| CYP21A2   | rs397515530| G                | A/A            |                  |                  |                  |
| DHRS4     | rs17099455 | G                | G/A            |                  |                  |                  |
| DYN1C2L11 | rs9309107  | T                | T/A            |                  |                  |                  |
| EDN1      | rs5370     | G                | G/T            |                  |                  | G/T              |
| EFS       | rs2231798  | T                | T/C            |                  |                  | T/C              |
| EPCAM     | rs1126497  | T                | T/C            |                  |                  | T/C              |
| FHAD1     | rs4661330  | A                | A/G            |                  |                  |                  |
| HNPP      | rs100803   | C                | C/T            |                  |                  | C/T              |
| HLA-C     | rs79636386 | A                | A/C            |                  |                  | C/C              |
| HLA-DQB1  | rs1130398  | C                | C/T            |                  |                  | C/T              |
| HLA-DQB1  | rs1063323  | C                | C/T            |                  |                  | C/T              |
| HLA-DQB1  | rs71547382 | C                | C/T            |                  |                  | C/T              |
| KIF28B    | rs1886997  | A                | A/G            |                  |                  | A/G              |
| KIF28B    | rs144593231| C                | C/CTAAAG       |                  |                  | C/CTAAAG         |
| KLHL33    | rs1953225  | T                | T/C            |                  |                  |                  |
| KRT40     | rs9908304  | G                | G/A            |                  |                  | G/A              |
| LRRC6     | rs2293797  | G                | A/A            |                  |                  | G/A              |
| MCCD1     | rs2259435  | G                | G/A            |                  |                  | G/A              |
| MHC1      | rs1085075 (EVS) | A            | A/G            |                  |                  | A/G              |
| MHC1      | rs1051788 (EVS) | G            | G/A            |                  |                  | G/A              |

Continued
10 years), they had the lowest lung function of the group. Finally, although the findings in the study are suggestive of an immune component playing a role in the development or avoidance of the disease, there is a need for further validation studies to confirm the associations found.

Table 4. Variants identified in non-affected subjects. Definition of abbreviations: SNP: single nucleotide polymorphism; EVS = present in Exome Variant Server. Genes linked to immunity are shown in bold and underlined characters. *novel = not present in any public database. 43% of the genes in the recessive inherited model and 24% in the dominant were immune.

| Gene name | SNP ID    | wild type allele | AWK (family 3) | AWL (family 185) | BIR (family 237) | BIF (family 114) |
|-----------|-----------|------------------|----------------|------------------|------------------|------------------|
| MMP27     | rs1276286 | T                | T/A            | T/A              | A/A              |                   |
| NOS2      | rs2297518 | G                | G/A            | G/A              |                   |                   |
| NPS2      | rs9223    | C                | C/T            | C/T              | C/T              | C/T              |
| NPY5R     | rs79871698| G                | G/A            | G/A              |                   |                   |
| NRG3      | rs1884282 | C                | C/G            | C/G              |                   |                   |
| NSUN4     | rs373774  | A                | A/G            | A/G              |                   |                   |
| NUMBL     | rs7496931 | T                | TTGCTGTGGTCT   | TTGCTGTGGTCT    | TTGCTGTGGTCT     | TTGCTGTGGTCT     |
| OR10G2    | rs41314525| C                | C/A            | C/A              |                   |                   |
| OR13C2    | rs1015474 | T                | T/C            | T/C              | T/C              |                   |
| OR13C5    | rs10991326| A                | A/T            | A/T              |                   |                   |
| OR13C5    | rs4117966 | C                | C/T            | C/T              | C/T              |                   |
| OR13C5    | rs1523678 | T                | T/C            | T/C              | T/C              |                   |
| OR13C5    | rs1851725 | A                | A/G            | A/G              |                   |                   |
| OR13C5    | rs6479260 | G                | G/C            | G/C              |                   |                   |
| OR13C5    | rs1131421 | GT               | GT/G           | GT/G             | GT/G             |                   |
| OR13C9    | rs993658  | T                | T/A            | T/A              |                   |                   |
| OR2T2     | rs6700848 | C                | C/T            | C/T              |                   |                   |
| OR4E2     | rs6173241 | C                | C/T            | C/T              |                   |                   |
| PRDM1     | rs811925  | C                | C/G            | C/G              |                   |                   |
| PSDMD9    | rs14259   | A                | A/G            | A/G              |                   |                   |
| RNLS      | rs2296545 | C                | C/G            | C/G              |                   |                   |
| SPATA16   | rs1515441 | C                | C/T            | C/T              |                   |                   |
| SPATA16   | rs16846616| C                | C/T            | C/T              |                   |                   |
| SVEP1     | rs3739451 | A                | A/T            | A/T              |                   |                   |
| TMEM1132C | rs1242159 | G                | G/A            | G/A              |                   |                   |
| TMEM71    | rs1895807 | A                | A/G            | A/G              |                   |                   |
| WDR66     | rs17852561| C                | C/T            | C/T              |                   |                   |
| WWCG2     | rs11734376| G                | G/T            | G/T              |                   |                   |
| ZNF626    | rs3002662 | T                | T/G            | T/G              |                   |                   |

Figure 3. Enrichment maps in Cytoscape3. This analysis integrates and visualizes data from Gene Ontology, KEGG and Reactome. Panel A shows the networks in affected subjects; panel B in non-affected subjects. The intensity of the colour in the node corresponds to level of significance (the darkest the node, the most significant the p-value).
In conclusion, to our knowledge, this is the first study that provides a detailed description of possible genetic susceptibility factors for emphysema in siblings with AATD. Our findings suggest that gene variants mainly involved in the regulation of immune homeostasis and the maintenance of self-tolerance could contribute to the development or suppression of the disease. The evidence that some of the gene's determinants identified in our study were previously described by GWAS in the development of COPD with normal AAT levels, adds to the significance of our results and highlights the similarities in the mechanisms of COPD/emphysema with or without AATD.

Methods
Extended methods for each aspect of the study and analysis plan are provided in the Online Supplement. Briefly, the study included 9 individuals from 4 different families in the Italian Registry for AATD36. The probands selected from the registry were aged ≥18 years with the presence of severe AAT deficiency, defined by the carriage of the PiZZ genotype, or null genotypic variants. Within the same family, we compared siblings who were concordant for genotype, but discordant for clinical presentation (i.e. emphysema or no emphysema). The presence of emphysema in the affected sibling (and its absence in non-affected ones) was determined by chest HRCT. To confirm that non-affected subjects were free of any respiratory disease we also required them to have a preserved lung function with normal diffusing capacity for carbon monoxide (DLco) and normal blood gases. To minimize the potential confounding effect of smoking, we have selected among the families in the Italian registry those whose smoking history was unremarkable (either nonsmokers or former smokers who had quit by >10 years and had ≤20 pack-years cumulative exposure). The study was approved by the Institutional Review Board (Policlinico San Matteo, Pavia) and complied with the principles set out in the Declaration of Helsinki. Informed consent was obtained from each participant regarding storage of biological samples and genetic sequencing. The clinical results are presented here in a fully anonymous form.

DNA was extracted from whole blood and genotyping performed as previously described37. Exome libraries were prepared using the Ion Proton Targeted Sequencing Library (Ion AmpliSeq™ Exome RDY Kit) with a minimum coverage of 80X. Data were processed with a pipeline developed by the bioinformatics unit of our university. We included only high confidence variants and variants that were non-synonymous, and excluded false positive variants in the reference genome. We did not apply any further filtering criteria, including both novel and annotated variants.

We analyzed affected and non-affected subjects considering different inheritance models: (a) recessive model (shared homozygosity in QueryOR); (b) dominant model (shared variants in QueryOR). The analysis was restricted to variants confirmed at least in three families out of four.

ANNOVAR38 and dbNSFP database (v.2.9)39 were used to integrate annotation, linking variants to genes, transcripts, proteins and biological ontologies. To further estimate the impact of variants on protein structure and function, we used scores that consider the functional impact on evolutionary conserved domains: CADD50, DANN51 and PROVEAN52. Novel variants were compared across multiple species in Ensembl40, to verify conservation. To determine if our gene lists were enriched in any functional categories or metabolic pathways, we performed analyses using DAVID41, Reactome42 and KEGG43. Finally, Enrichment map app44 was used to visualize the enriched gene-set as a network in Cytoscape3 platform45. We used simulations with other families (without AATD), to assess the power of this approach under different levels of genetic heterogeneity (data not shown).

References
1. Mastrangeli, A. & Crystal, R. G. Alpha 1-antitrypsin An introduction. In Alpha 1-antitrypsin deficiency, Biology, Pathogenesis, Clinical manifestations, Therapy 88, 3–18 (Crystal RG, 1996).
2. Hay, J. G., Suzuki, M. & Crystal, R. G. Alpha1-antitrypsin gene and promoter. In Alpha 1-antitrypsin deficiency, Biology, Pathogenesis, Clinical manifestations, Therapy 88, 21–31 (Crystal RG, 1996).
3. Baraldo, S. et al. Immune activation in alpha1-antitrypsin-deficiency emphysema. Beyond the protease-antiprotease paradigm. Am. J. Respir. Crit. Care Med. 191, 402–409 (2015).
4. Jonigk, D. et al. Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase. Proc. Natl. Acad. Sci. U.S.A. 110, 15007 (2013).
5. Jancauskienė, S. M. et al. The discovery of α1-antitrypsin and its role in health and disease. Respir. Med. 105, 1129–1139 (2011).
6. Lomas, D. A., Evans, D. D., Finch, J. T. & Carrell, R. W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 357, 605–607 (1992).
7. Lee, J. H. & Brantly, M. Molecular mechanisms of alpha1-antitrypsin null alleles. Respir. Med. 94(Suppl C), S7–11 (2000).
8. Hatipoglu, U. & Stoller, J. K. α1-Antitrypsin Deficiency. Rare Orphan Lung Dis. 37, 487–504 (2016).
9. Laurell, C. B. & Eriksson, S. The electrophoretic alpha1-globulin pattern of serum in alpha1-antitrypsin deficiency. 1963. Cephal 10, 3–8 (2013).
10. Bergin, D. A., Hurley, K., McElvaney, N. G. & Reeves, E. P. Alpha 1-antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent. Arch. Immunol. Ther. Exp. (Warsz.) 60, 81–97 (2012).
11. Tobin, M. J., Cook, P. J. & Hutchison, D. C. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pt Z. A survey by the British Thoracic Association. Br. J. Dis. Chest 77, 14–27 (1983).
12. Stoller, J. K. & Abouassouan, L. S. α1-antitrypsin deficiency. The Lancet 365, 2225–2236 (2005).
13. DeMeo, D. L. et al. Determinants of airflow obstruction in severe alpha 1-antitrypsin deficiency. Thorax 62, 806 (2007).
14. Wittes, J. & Wu, M. C. Natural history of Alpha1-antitrypsin. In Alpha 1-antitrypsin deficiency, Biology, Pathogenesis, Clinical manifestations, Therapy 88, 281–291 (Crystal RG, 1996).
15. Cooper, D. N., Krawczyk, M., Polychronakos, C., Tyler-Smith, C. & Kehrer-Sawatzki, H. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetration in human inherited disease. Hum. Genet. 132, 1077–1130 (2013).
16. Katsanis, N. The continuum of causality in human genetic disorders. Genome Biol. 17, 233 (2016).
17. Harper, A. R., Nayee, S. & Topol, E. J. Protective alleles and modifier variants in human health and disease. Nat. Rev. 16, 689–701 (2015).
18. Banshad, M. J. et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat. Rev. Genet. 12, 745 (2011).
19. Rigobello, C. et al. Exome sequencing in diseased and healthy subjects with alpha 1 antitrypsin deficiency. In European Respiratory Journal (2017).
20. Bertoldi, L. et al. QueryOR: a comprehensive web platform for genetic variant analysis and prioritization. *BMC Bioinformatics* **18**, 225–017–1654–4 (2017).
21. Cosio, M. G., Saetta, M. & Agusti, A. Immunologic aspects of chronic obstructive pulmonary disease. *N. Engl. J. Med.* **360**, 2445–2454 (2009).
22. Suzuki, M. et al. The cellular and molecular determinants of emphysematous destruction in COPD. *Sci. Rep.* 7, 9562 (2017).
23. Looney, B. M., Xia, C.-Q., Concannon, P., Ostrov, D. A. & Clare-Salzler, M. J. Effects of type 1 diabetes-associated IFIH1 polymorphisms on MA3 function and expression. *Curr. Diab. Rep.* **15**, 96–015–0656–8 (2015).
24. Enevold, C. et al. Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. *J. Neuroimmunol.* **212**, 125–131 (2009).
25. Martinez-Nava, G. A. et al. The association of AKNA gene polymorphisms with knee osteoarthritis suggests the relevance of this immune response regulator in the disease genetic susceptibility. *Mol. Biol. Rep.* **45**, 151–161 (2018).
26. Matsuda, A. et al. Large-scale identification and characterization of human genes that activate NF-κB and MAPK signaling pathways. *Oncogene* **22**, 3307 (2003).
27. Hancock, D. B. et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. *Nat. Genet.* **42**, 45–52 (2010).
28. Repapi, E. et al. Genome-wide association study identifies five loci associated with lung function. *Nat. Genet.* **42**, 36–44 (2010).
29. Wu, L., Ma, L., Nicholson, F. & Black, P. N. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. *Respir. Med.* **105**, 329–336 (2011).
30. Manichaud, A. et al. Genome-wide study of percent emphysema on computed tomography in the general population. The Multi-Ethnic Study of Atherosclerosis Lung/SNP Health Association Resource Study. *Am. J. Respir. Crit. Care Med.* **189**, 408–418 (2014).
31. Gregersen, P. K. et al. REL, encoding a member of the NF–κB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. *Nat. Genet.* **41**, 820 (2009).
32. Edmiston, J. S. et al. Gene expression profiling of peripheral blood leukocytes identifies potential novel biomarkers of chronic obstructive pulmonary disease in current and former smokers. *Biomark. Biochem. Indic. Exp. Response Susceptibility Chem.* **15**, 715–730 (2010).
33. Faner, R. et al. Network Analysis of Lung Transcriptomics Reveals a Distinct B-Cell Signature in Emphysema. *Am. J. Respir. Crit. Care Med.* **193**, 1242–1253 (2016).
34. Qiu, W. et al. Genetics of spumonum gene expression in chronic obstructive pulmonary disease. *PloS One* **6**, e24395 (2011).
35. Kumar, A. et al. Antigenic peptide molecular recognition by the DRB1-DQB1 haplotype modulates multiple sclerosis susceptibility. *Mol. Biosyst.* **10**, 2043–2054 (2014).
36. Furukawa, H. et al. The role of common protective alleles HLA-DRB1*13 among systemic autoimmune diseases. *Genes Immun.* **18**, 1–7 (2017).
37. Cenit, M. C. et al. Analysis of ancestral and functionally relevant CDS variants in systemic lupus erythematosus patients. *PloS One* **9**, e13090 (2014).
38. Tabbakh, M., Mokrani-Hammani, M., Bismuth, G. & Mami-Chouaib, F. T-cell modulatory properties of CDS and its role in antitumor immune responses. *Oncomimunology* **2**, e22841 (2013).
39. Patel, S. & Jin, L. TMEM173 variants and potential importance to human biology and disease. *Genes Immun.. https://doi.org/10.35718-018-0029-9 (2018).
40. Song, J. J. et al. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. *J. Clin. Invest.* **121**, 3517–3527 (2011).
41. Baraldo, S. Advances in chronic obstructive pulmonary disease genetics: building the picture one piece at a time. *Lancet Respir. Med.* **7**, 371–372 (2019).
42. Hobbs, B. D. et al. Exome Array Analysis Identifies a Common Variant in IL27 Associated with Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med.* **194**, 48–57 (2016).
43. Bossé, Y. et al. Early-onset emphysema in a large French-Canadian family: a genetic investigation. *Lancet Respir. Med.* **7**, 427–436 (2019).
44. Morrow, J. D. et al. Functional interactors of three genome-wide association study genes are differentially expressed in severe chronic obstructive pulmonary disease lung tissue. *Sci. Rep.* **7**, 44232 (2017).
45. Sandhaus, R. A. et al. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. *Chronic Obstr Pulm Dis. 3*, 668–682 (2016).
46. Luissetti, M. et al. Italian registry of patients with alpha-1 antitrypsin deficiency: general data and quality of life evaluation. *CopaD (Suppl 1), 52–57 (2015).
47. Ferrarotti, I. et al. Laboratory diagnosis of alpha-1 antitrypsin deficiency. *Transl. Res. J. Lab. Clin. Med.* **150**, 267–274 (2007).
48. Yang, H. & Wang, K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. *Nat. Protoc.* **10**, 1556–1566 (2015).
49. Liu, X., Jian, X. & Boerwinkle, E. dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. *Hum. Mutat.* **34**, E2393–2402 (2013).
50. Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat. Genet.* **46**, 310–315 (2014).
51. Quang, D., Chen, Y. & Xie, X. DANN: a deep learning approach for annotating the pathogenicity of genetic variants. *Bioinforma. Oxf. Engl. 31*, 761–765 (2015).
52. Choi, Y. & Chan, A. P. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. *Bioinforma. Oxf. Engl. 31*, 2745–2747 (2015).
53. Herrero, J. et al. Ensembl comparative genomics resources. *Database 2016*, bav096–bav096 (2016).
54. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **4**, 44 (2008).
55. Croft, D. et al. The Reactome pathway knowledgebase. *Nucleic Acids Res.* **42**, D472–7 (2014).
56. Kanehisa, M., Goto, S., Sato, Y., Furumichi, M. & Tanabe, M. KEGG for integration and interpretation of large-scale molecular data sets. *Nucleic Acids Res.* **40**, D109–14 (2012).
57. Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation. *PLOS ONE* **5**, e13984 (2010).
58. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* **13**, 2499–2504 (2003).

**Acknowledgements**

The authors thank Dr. Christine Seebacher for her invaluable effort in the study, helping in patient collection and Dr. Filippo Navaglia for help in setting up experimental conditions. Funding: CHEST Foundation and the Alpha-1 Foundation Research Grant (2015), University of Padova (CDPA150070) and Fondazione IRCCS Policlinico San Matteo Ricerca Corrente - RC721.
**Author Contributions**
Conception and design: C.R., S.B., G.V., M.S. and M.G.C.; analysis and interpretation: C.R., S.B., M.T., E. Bazzan, G.T., G.V., M.S. and M.G.C.; patient recruitment and clinical analysis: I.F., A.G.C., E. Balestro and D.B.; drafting the manuscript for important intellectual content: C.R., S.B., M.T., M.S. and M.G.C.

**Additional Information**
*Supplementary information* accompanies this paper at [https://doi.org/10.1038/s41598-019-49409-1](https://doi.org/10.1038/s41598-019-49409-1).

**Competing Interests:** M.S. has received unrestricted research grants from Takeda Ltd, Chiesi Farmaceutici, Laboratori Guidotti Spa, outside this specific study.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

© The Author(s) 2019